Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with paclitaxel and carboplatin for recurrent platinum-sensitive epithelial ovarian cancer
2006-007013-20Phase 2Terminated
- Sponsor
- Onkologisk afdeling R and the Unit for Experimental Chemotherapy
- Start
- Jan 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat, paclitaxel and carboplatin in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Onkologisk afdeling R and the Unit for Experimental Chemotherapy. Primary endpoint: Objective response rate. Started Jan 2007; status: terminated.
02
Drugs
vorinostatpaclitaxelcarboplatin
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2006-007013-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007013-20.